Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Morpholine | HCID 8083 | — |
| Reactant | Sodium Bicarbonate | HCID 516892 | — |
| Reactant | Sodium triacetoxyborohydride | HCID 5049666 | — |
| Reactant | HCID 58011768 | HCID 58011768 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Product | HCID 58011820 | HCID 58011820 | — |
Reaction Steps
0.10 g (0.21 mmol) of 2-[3-(4-chlorophenyl)-4-(2-oxoethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-N-{1-methyl-1-[3-(trifluoromethyl)phenyl]ethyl}-acetamide from Example 401 are dissolved in 30 ml of dichloromethane and 0.4 ml of DMF and stirred with 22 mg (0.2 mmol) of morpholine for 1 hr at RT. Next, 66 mg (0.31 mmol) of sodium triacetoxyborohydride are added and the mixture is stirred for 18 hrs at RT. The reaction mixture is treated with 10 ml of saturated sodium hydrogen carbonate solution and extracted three times with 10 ml ethyl acetate each time. The combined organic phases are dried over sodium sulphate, filtered and concentrated in vacuo. The crude product is purified by preparative HPLC [Method 10]. 11.0 mg (10% of theory) of the target compound are obtained.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08084481B2 |
|---|
| Source dataset | uspto-grants-2011_12 |
|---|
| ORD ID | ord-db6b7299f56e486897d6eb43883eb001 |
|---|
| Source note | uspto-grants-2011_12 |
|---|